1. Executive Summary and Strategic Context

The GENEROUS Model is a voluntary Medicaid drug pricing model testing international reference pricing for prescription drugs in the Medicaid Drug Rebate Program (MDRP). Announced in 2025, GENEROUS addresses the growing disparity between U.S. and international drug prices within Medicaid, where net drug spending reached $60 billion in 2024 (up $10 billion from 2022). The model is the first Medicaid-focused drug pricing initiative using CMS-led negotiations with manufacturers on behalf of state Medicaid programs.

Unlike GLOBE and GUARD (mandatory models for Medicare Parts B and D), GENEROUS is voluntary for both pharmaceutical manufacturers and state Medicaid agencies. Participating manufacturers enter CMS-negotiated agreements to provide supplemental rebates that align Medicaid net prices with what select comparable countries pay. States implement uniform, transparent coverage criteria for participating drugs.

1.1 Strategic Significance

GENEROUS leverages CMS's collective negotiating power on behalf of 50+ state Medicaid programs, creating a single federal negotiation channel rather than state-by-state negotiations. This centralized approach could generate significant savings across the $60 billion annual Medicaid drug spend while improving formulary consistency across states. The model also tests whether voluntary international reference pricing can achieve meaningful price reductions without the legal challenges associated with mandatory models.

2. Model Architecture

2.1 Regulatory Framework

Authority: Section 1115A of the Social Security Act.

Announcement: 2025 (preceded GLOBE/GUARD announcements).

Type: VOLUNTARY for manufacturers and states.

Duration: 5 years.

RFA: Released 2025, currently accepting enrollment.

2.2 How It Works

Step 1: Participating drug manufacturers enter CMS-led negotiated agreements.

Step 2: Pricing set based on international pricing data from select comparable countries.

Step 3: Manufacturers provide supplemental rebates to participating state Medicaid programs (above existing Medicaid statutory rebates).

Step 4: States invoice manufacturers for supplemental rebates.

Step 5: CMS shares in rebates through reduced federal Medicaid payments (FMAP adjustment).

Step 6: Participating states implement uniform, transparent coverage criteria for GENEROUS drugs.

2.3 Participation Requirements

Manufacturers: Must participate in the Medicaid Drug Rebate Program. Agree to CMS-negotiated supplemental rebate terms based on international pricing benchmarks.

States: State Medicaid agencies voluntarily enroll. Must implement uniform coverage criteria for participating drugs. Must invoice manufacturers and report rebate data to CMS.